CompletedPhase 4NCT03735537

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid

Studying Osteogenesis imperfecta

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Edinburgh
Principal Investigator
Stuart Ralston, MD, MD
University of Edinburgh
Intervention
Teriparatide Pen Injector(drug)
Enrollment
350 target
Eligibility
18 years · All sexes
Timeline
2016 – 2025

Study locations (23)

Collaborators

NHS Lothian

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03735537 on ClinicalTrials.gov

Other trials for Osteogenesis imperfecta

Additional recruiting or active studies for the same condition.

See all trials for Osteogenesis imperfecta →

← Back to all trials